drugset / Trial / NCT00864851
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.
Timeline
- Start
- 2008-12-29
- Primary completion
- 2012-06-01
- Completion
- 2012-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Replagal | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |
| Comparator | Replagal | Protein / enzyme biologic | 0.4 mg/kg | Intravenous |